Trine Frederiksen

Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data

E. Molden, B. M. Wollmann, R. L. Smith, 2021, Clinical Pharmacokinetics.

Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine

K. Brøsen, T. Stage, J. Areberg, 2021, CPT: pharmacometrics & systems pharmacology.

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine

K. Brøsen, J. Areberg, Tore Bjerregaard Stage, 2020, Clinical pharmacology and therapeutics.

Strategic Development of Product-Service Systems (PSS) through Archetype Assessment

Tim C. McAloone, Trine Brink Frederiksen, Marina P. P. Pieroni, 2021, Sustainability.

Does ethnicity impact CYP2D6 genotype–phenotype relationships?

K. Brøsen, T. Stage, J. Areberg, 2023, Clinical and translational science.

Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of Brexpiprazole

K. Brøsen, T. Stage, J. Areberg, 2022, Clinical pharmacology and therapeutics.

Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching

E. Molden, M. Jukic, R. L. Smith, 2022, Journal of clinical psychopharmacology.

Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype–phenotype translation

Trine Frederiksen, 2023, Basic & clinical pharmacology & toxicology.